-
公开(公告)号:US20160115128A1
公开(公告)日:2016-04-28
申请号:US14898633
申请日:2014-08-08
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: Jumpei AIDA , Yayoi YOSHITOMI , Yuko HITOMI , Naoyoshi NOGUCHI , Yasuhiro HIRATA , Hideki FURUKAWA , Akito SHIBUYA , Koji WATANABE , Yasufumi MIYAMOTO , Tomohiro OKAWA , Nobuyuki TAKAKURA , Seiji MIWATASHI
IPC: C07D211/34 , C07D413/10 , C07D401/14 , C07D405/12 , C07D413/14 , C07D401/10 , C07D401/12
CPC classification number: C07D211/34 , C07D211/22 , C07D213/30 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/10 , C07D413/14
Abstract: Provided is a novel aromatic ring compound having a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity and a GLP-1 secretagogue action, is useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and affords superior efficacy.
Abstract translation: 提供具有GPR40激动剂活性和GLP-1促分泌作用的新型芳环化合物。 由下式表示的化合物:其中每个符号如说明书所述,或其盐具有GPR40激动剂活性和GLP-1促分泌素作用,可用于预防或治疗癌症,肥胖症,糖尿病,高血压, 高脂血症,心力衰竭,糖尿病并发症,代谢综合征,肌肉减少症等,具有优异的疗效。